Genovate Biotechnology Co (ROCO:4130) EBIT per Share: NT$0.13 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4130 Genovate Biotechnology Co Ltd ROCO:4130
72 GF Score
Price NT$26.80
GF Value NT$22.21
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Genovate Biotechnology Co EBIT per Share?

Genovate Biotechnology Co ROCO:4130 72 EBIT per Share is NT$0.13 as of Dec. 2025. GuruFocus rates ROCO:4130 with a GF Score™ of 72/100 and a GF Value™ of NT$22.21 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 1,173 Biotechnology companies, Genovate Biotechnology Co ranks worse than 85251.41% on this metric.

Genovate Biotechnology Co's EBIT per Share for the three months ended in Dec. 2025 was NT$-0.05. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.13.

During the past 12 months, the average EBIT per Share Growth Rate of Genovate Biotechnology Co was -70.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Genovate Biotechnology Co's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Genovate Biotechnology Co was 283.00% per year. The lowest was -79.10% per year. And the median was 33.15% per year.

ROCO:4130's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Genovate Biotechnology Co's EBIT for the three months ended in Dec. 2025 was NT$-5.6 Mil.

Genovate Biotechnology Co  (ROCO:4130) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Genovate Biotechnology Co EBIT per Share Related Terms

Genovate Biotechnology Co EBIT per Share Historical Data

* Premium members only.

The historical data trend for Genovate Biotechnology Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovate Biotechnology Co EBIT per Share Chart

Genovate Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 -0.08 0.26 0.27 0.12

Genovate Biotechnology Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 0.11 0.08 -0.01 -0.05
ROCO:4130
72GF Score
Genovate Biotechnology Co Ltd ROCO:4130
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genovate Biotechnology Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Genovate Biotechnology Co's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=14.137/117.537
=0.12

Genovate Biotechnology Co's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-5.565/117.448
=-0.05

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of NT$0.13 mean?
Genovate Biotechnology Co (ROCO:4130) has a EBIT per Share of NT$0.13 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genovate Biotechnology Co and its competitors. According to the industry distribution chart, Genovate Biotechnology Co ranks #999999 out of 1173 companies in the Biotechnology industry.
Is Genovate Biotechnology Co's EBIT per Share too high?
Genovate Biotechnology Co's current EBIT per Share is NT$0.13. Based on the distribution chart, Genovate Biotechnology Co ranks #999999 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genovate Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovate Biotechnology Co ranks #999999 out of 1173 companies for EBIT per Share. This places Genovate Biotechnology Co in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genovate Biotechnology Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genovate Biotechnology Co's current EBIT per Share is NT$0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.21, compared to a current price of NT$26.80 — trading 20.7% above its estimated fair value. The current EBIT per Share is NT$0.13. Genovate Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current EBIT per Share is NT$0.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?

Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued. The current stock price of NT$26.80 is trading 20.7% above its estimated GF Value™ of NT$22.21. GuruFocus considers Genovate Biotechnology Co to be Modestly Overvalued.

Key valuation signals for ROCO:4130:

  • EBIT per Share: NT$0.13
  • GF Value™: NT$22.21 vs. price of NT$26.80 (20.7% above fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genovate Biotechnology Co Business Description

Address No.1, First Industrial Road, Hsin-Chu Expanded Park, Hukou Township, Guangdong Province, Hsin-Chu county, Hsin-Chu, TWN, 303036
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
72GF Score

Get the complete analysis for ROCO:4130

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.80
Price
NT$22.21
GF Value